Hengrui Medicine: The Phase II clinical trial of SHR-A2009 has been approved, with a cumulative R&D investment of approximately 329 million yuan.

Hengrui Medicine announced that its subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd. have recently received the "Drug Clinical Trial Approval Notice" approved by the National Medical Products Administration for SHR-A2009 injection and Aderakimab injection. They are authorized to conduct a Phase II clinical trial of SHR-A2009 in combination with Aderakimab, or in combination with third-generation EGFR TKI in patients with non-small cell lung cancer, which will begin in the near future. The total research and development investment for the SHR-A2009 project amounts to approximately 329 million yuan, while the total research and development investment for the Aderakimab injection project amounts to approximately 1.252 billion yuan.